EC Microbiology

Review Article Volume 20 Issue 9 - 2024

Intestinal Microbiota Transplantation and Chronic Alcoholism

Aacute;lvaro Zamudio Tiburcio1*, Héctor Bermúdez Ruiz2, Silverio Alonso López3 and Pedro Antonio Reyes López4

1Department of Gastroenterology, Intestinal Microbiota Transplantation Medical Specialties Naples Unit, Mexico

2Endoscopy Service, Oncology Hospital, National Medical Center, XXI Century, Mexican Social Security Institute, Hospital Trinidad, Mexico City, Mexico

3Department of Urologist, Chairman Medical Specialties Naples in Mexico City, Mexico

4Immunologist, Rheumatologist, National Institute of Cardiology “I. Chávez”, Mexico City, Mexico

*Corresponding Author: Álvaro Zamudio Tiburcio, Department of Gastroenterology, Intestinal Microbiota Transplantation Medical Specialties Naples Unit, Mexico.
Received: February 11, 2024; Published: February 26, 2024




Numerous articles appear in world literature on various conditions that can be modulated with intestinal microbiota transplantation, with no exception being a topic as transcendent as chronic alcoholism and its different complications. Highlighting alcoholic hepatitis and alcohol-nutritional liver cirrhosis. This has motivated us to carry out a review, although small, in order to evaluate the different trends of the effect of microorganisms on frequent or rare conditions, becoming a new strategy, not insignificant.

The increase in alcohol consumption has impacted the most serious process of liver disease: “Alcoholic hepatitis”. As the number of cases increases, on the one hand good medical action is made difficult, and on the other hand morbidity and mortality are increased, which puts us in an uncomfortable position in the face of this growing number of cases. Fortunately, evidence is growing that many chronic alcoholic liver diseases have a close connection with the intestinal microbiota.

 Keywords: Chronic Alcoholic Liver Disease (CALD); Alcoholic Hepatitis (AH); Microbiome (M); Intestinal Microbiota (IM); Fecal Microbiota Transplantation (FMT)

  1. Meroni M., et al. “Genetic and epigenetic modifiers of alcoholic liver disease”. International Journal of Molecular Sciences 12 (2018): 3857.
  2. Shasthry SM. “Fecal microbiota transplantation in alcohol related liver diseases”. Clinical and Molecular Hepatology 3 (2020): 294-301.
  3. Llopis M., et al. “Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease”. Gut 5 (2016): 830-839.
  4. Jasmohan S Bajaj and Alexander Khoruts. “Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis”. Journal of Hepatology5 (2020): 1003-1027.
  5. Grønbæk M. “The positive and negative health effects of alcohol-and the public health implications”. Journal of the Internal Medicine4 (2009): 407-420.
  6. Petersen C and Round JL. “Defining dysbiosis and its influence on host immunity and disease”. Cellular Microbiology 7 (2014): 1024-1033.
  7. DeGruttola AK., et al. “Current understanding of dysbiosis in disease in human and animal models”. Inflammatory Bowel Diseases 5 (2016): 1137-1150.
  8. Litwinowicz K., et al. “Changes in the composition of the human intestinal microbiome in alcohol use disorder: a systematic review”. The American Journal of Drugs and Alcohol Abuse1 (2020): 4-12.
  9. Smirnova E., et al. “Fecal microbiome distinguishes alcohol consumption from alcoholic hepatitis but does not discriminate disease severity”. Hepatology1 (2020): 271-286.
  10. Mutlu EA., et al. “Colonic microbiome is altered in alcoholism”. Gastrointestinal and Liver Physiology9 (2012): G966-G978.
  11. Neuman MG., et al. “Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage”. Experimental and Molecular Pathology1 (2017): 162-180.
  12. Day AW and Kumamoto CA. “Gut microbiome dysbiosis in alcoholism: consequences for health and recovery”. Frontiers in Cellular and Infection Microbiology 12 (2020): 840164.
  13. Meroni M., et al. “Alcohol or gut microbiota: who is the guilty?” International Journal of Molecular Sciences 18 (2019): 4568.
  14. Gorky K and Schwaber J. “The role of the gut-brain axis in alcohol disorders”. Progress in Neuro- Psychopharmacology and Biological Psychiatry 65 (2016): 234-241.
  15. Stärkel P., et al. “Chapter 17. Alcohol-dependence and the microbiota-gut-brain axis”. Editor(s): Niall Hyland, Catherine Stanton, The Gut-Brain Axis, Academic Press (2016): 363-390.
  16. Bajaj JS. “Alcohol, liver disease and the gut microbiota”. Nature Reviews Gastroenterology and Hepatology 4 (2019): 235-246.
  17. Gupta H., et al. “Gut microbiota at the intersection of alcohol, brain, and the liver”. Journal of Clinical Medicine 3 (2021): 541.
  18. Ding JH., et al. “Role of gut microbiota via the gut-liver- brain axis in digestive diseases”. World Journal of Gastroenterology40 (2020): 6141-6162.
  19. Tsiaoussis GI., et al. “Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications”. World Journal of Hepatology 17 (2015): 2058-2068.
  20. Ghosh SS., et al. “Intestinal barrier function and metabolic/liver diseases”. Liver Research2 (2020): 81-87.
  21. Plaza-Díaz J., et al. “The gut barrier, intestinal microbiota, and liver disease: molecular mechanisms and strategies to manage”. International Journal of Molecular Sciences 21 (2020): 8351.
  22. Chopyk DM and Grakoui A. “Contribution of the intestinal microbiome and gut barrier to hepatic disorders”. Gastroenterology 3 (2020): 849-863.
  23. Wang SC., et al. “Alcohol addiction, gut microbiota, and alcoholism treatment: a review”. International Journal of Molecular Sciences 17 (2020): 6413.
  24. Philips CA., et al. “Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis”. Indian Journal of Gastroenterology 3 (2018): 215-225.
  25. Philips CA., et al. “Modulating the intestinal microbiota: therapeutic opportunities in liver disease”. Journal of Clinical and Translational Hepatology1 (2020): 87-99.
  26. Anirvan P., et al. “Fecal microbiota transplantation in alcoholic hepatitis: new treatment paradigm or a shot in the dark?” Hepatology International 5 (2023): 1318-1319.
  27. Pohl K., et al. “The effect of increasing intestinal short-chain fatty acid concentration on gut permeability and liver injury in the context of liver disease: A systematic review”. Journal of Gastroenterology and Hepatology 8 (2022): 1498-1506.
  28. Zhang T., et al. “Butyrate ameliorates alcoholic fatty Liver disease via reducing endotoxemia and inhibiting liver gasdermin D-mediated pyroptosis”. Annals of Translational Medicine 10 (2021): 873.
  29. Visekruna V and Luu M. “The role of short-chain fatty acids and bile acids in intestinal and liver function, inflammation, and carcinogenesis”. Frontiers in Cell and Developmental Biology 9 (2021): 703218.
  30. Martino C., et al. “Acetate reprograms gut microbiota during alcohol consumption”. Nature Communications 13 (2022): 4630.
  31. Keeley AF., et al. “Ultrastructure of hyaline cytoplasmic inclusions in a human hepatoma: relationship to mallory's alcoholic hyalin”. Gastroenterology2 (1972): 280-293.
  32. Tadokoro T., et al. “Nutritional support for alcoholic liver disease”. Nutrients6 (2023): 1360.
  33. Bajaj JS and Khoruts A. “Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis”. Journal of Hepatology 5 (2020): 1003-1027.
  34. Acharya C and Bajai JS. “Chronic liver diseases and the microbiome-translating”. Gastroenterology 2 (2021): 556-572.
  35. Zhao B., et al. “Evaluation of the efficacy of steroid therapy on acute liver failure”. Experimental and Therapeutic Medicine 5 (2016): 3121-3129.
  36. Xue R and Meng O. “The management of glucocortidcoids therapy in liver failure”. Frontiers in Immunology 10 (2019): 2490.
  37. Maddrey WC., et al. “Corticosteroid therapy of alcoholic hepatitis”. Gastroenterology 2 (1978): 193-199.
  38. Saberi B., et al. “Current management of alcoholic hepatitis and future therapies”. Journal of Clinical and Translational Hepatology 2 (2016): 113-122.
  39. Archa R and Tency NK. “Efficacy of fecal microbiota transplant in the treatment of severe alcoholic hepatitis compared to standard of care in humans a systematic review”. Journal of Medicine and Health Research (2023).
  40. Ikuta K., et al. “Control of immunity and allergy by steroid hormones”. Allergology International 4 (2022): 432-436.
  41. Pande A., et al. “Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial”. Hepatology International 1 (2023): 249-261.
  42. Kakihana K., et al. “Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut”. Blood6 (2016): 2083-2088.
  43. Huang C., et al. “Fecal microbiota transplantation versus glucocorticoids for the induction of remission in mild to moderate ulcerative colitis”. Journal of Translational Medicine1 (2022): 354.
  44. Cui B., et al. “Step-up fecal microbiota transplantation strategy: a pilot study for steroid-dependent ulcerative colitis”. Journal of Translation Medicine 13 (2015): 298.
  45. Louvet A., et al. “Effect of prophylactic antibiotics on mortality in severe alcohol-related hepatitis: a randomized clinical trial”. Journal of the American Medical Association18 (2023): 1558-1566.
  46. Jung JH., et al. “Gut microbiota-modulating agents in alcoholic liver disease: links between host metabolism and gut microbiota”. Frontiers in Medicine (Lausanne) 9 (2022): 913842.
  47. Jin MK., et al. “Fluoroquinolone antibiotics disturb the defense system, gut microbiome, and antibiotic resistance genes of Enchytraeus crypticus”. Journal of Hazardous MaterialsPart C (2022): 127509.
  48. Li F., et al. “Probiotics and alcoholic liver disease: treatment and potential mechanisms”. Gastroenterology Research and Practice (2016): 5491465.
  49. Gu Z., et al. “Probiotics for alleviating alcoholic liver injury”. Gastroenterology Research and Practice (2019): 9097276.
  50. Khoruts A and Sadowsky MJ. “Understanding the mechanisms of faecal microbiota transplantation”. Nature Reviews Gastroenterology and Hepatology 9 (2016): 508-516.
  51. Li S., et al. “Recent insights into the role of immune cells in alcoholic liver disease”. Frontiers in Immunology 10 (2019): 1328.
  52. Godfrey DI., et al. “The biology and functional importance of MAIT cells”. Nature Immunology 9 (2019): 1110-1128.
  53. Boicean A., et al. “Fecal microbiota transplantation in liver cirrhosis”. Biomedicines11 (2023): 2930.
  54. Sharma A., et al. “Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial”. Hepatology International2 (2022): 433-446.
  55. Suk KT and Koh H. “New perspective on fecal microbiota transplantation in liver diseases”. Journal of Gastroenterology and Hepatology1 (2021): 24-33.
  56. Paratore M., et al. “Fecal microbiota transplantation in patients with HBV infection or other chronic liver diseases: update on current knowledge and future perspectives”. Clinical Medicine 12 (2021): 2065.

Álvaro Zamudio Tiburcio., et al. “Intestinal Microbiota Transplantation and Chronic Alcoholism”. EC Microbiology  20.9 (2024): 01-10.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net